Related Experiment Video
Updated: Jun 14, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Mechanical circulatory support for AMI and cardiogenic shock
Yasir Abu-Omar1, Steven S L Tsui
1Transplant Unit, Papworth Hospital, Cambridge, United Kingdom.
Journal of Cardiac Surgery
|March 25, 2010
Summary
Cardiogenic shock after heart attack has a poor outlook, but early use of mechanical circulatory support devices (MCSD) can improve outcomes. Increased clinician awareness of these devices is crucial for better patient care.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock post-myocardial infarction (MI) affects 5-10% of patients with high mortality.
- Advancements in mechanical circulatory support devices (MCSD) are changing treatment strategies.
- Early MCSD intervention before end-organ dysfunction is linked to improved patient outcomes.
Purpose of the Study:
- To highlight the importance of mechanical circulatory support devices (MCSD) in managing post-myocardial infarction cardiogenic shock.
- To emphasize the need for earlier MCSD deployment to improve patient prognosis.
- To address the gap in clinician awareness regarding available MCSD options.
Main Methods:
- Literature review on current treatment paradigms for cardiogenic shock post-MI.
- Analysis of outcomes associated with early versus late MCSD deployment.
- Assessment of perceived limitations and clinical application frequency of existing MCSD.
Main Results:
- Early MCSD deployment is associated with better outcomes in post-MI cardiogenic shock.
- Existing MCSD are underutilized due to perceived limitations.
- There is a significant need to enhance clinician awareness of MCSD.
Conclusions:
- Mechanical circulatory support devices (MCSD) represent a critical therapeutic option for cardiogenic shock post-MI.
- Timely initiation of MCSD is essential for improving survival rates.
- Increased education and awareness among clinicians are necessary to optimize the use of MCSD in this patient population.
Related Concept Videos
01:24Blood Pressure Imbalances and Circulatory Shock
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...